Facebook-f Instagram Twitter Linkedin-in
  • info@viridiontherapeutics.com
Viridion Therapeutics Logo
Contact
Lead Candidate

CARG-2020: First-in-Class Multifunctional Immunotherapy.

Viridion's lead therapeutic candidate is designed to prevent recurrence in solid tumors. Built on the AVIDIO™ platform, CARG-2020 reprograms the tumor microenvironment by engaging three immune-suppression mechanisms simultaneously, in a single localized therapy.
First-in-Class
3 Mechanisms · 1 Construct
Pre-IND Completed
3 Tumor Types Validated

First-in-Class

3 Mechs . 1 Construct

Pre-IND Completed

FDA feedback received

3 Tumor Types

Validated perclinically

$9.7B

Lead indication market

Our Approach

One Construct. Three Mechanisms.

Developed at CaroGen Corporation, a Yale School of Medicine spin-off, CARG-2020 expresses three therapeutic molecules that engage all three suppression mechanisms simultaneously in a single therapeutic construct.
IL-12

Activates Anti-Tumor Immunity

Reprograms the suppressed tumor microenvironment into an active anti-tumor T-cell response — restoring immune recognition of residual cancer cells.

IL-17
(dn-IL-17RA)

Neutralizes Inflammation

A dominant-negative IL-17 receptor antagonist dismantles the chronic inflammatory shield that protects residual tumors from immune attack.

PD-L1 shRNA

Silences Checkpoints

Targeted PD-L1 silencing prevents tumor cells from evading the immune system — the same pathway as FDA-approved checkpoint inhibitors, delivered locally.

No other therapy currently in development combines all three mechanisms in a single construct.
De-Risked by Design

Every Component Clinically Validated.

CARG-2020 is novel as a combination, but each of its three components has independent clinical precedent.
Component
Clinical Precedent
Market
IL-12
Multiple Phase I/II trials demonstrating tumor immunity activation
Validated
PD-L1 Blockade
Standard of care across 15+ cancer types (Keytruda, Tecentriq)
$40B+
IL-17 Pathway
Approved in autoimmune disease (secukinumab); emerging oncology data
Validated
Lead Indication

Recurrent Ovarian Cancer.

CARG-2020's first clinical indication is recurrent platinum-resistant ovarian cancer — a population with high unmet need and limited treatment options. Intraperitoneal delivery enables a capital-efficient Phase I/Ib trial pathway.
~22K

U.S. Diagnoses Per Year

New ovarian cancer diagnoses annually in the United States.

~70%

Recurrence Rate

Patients experience disease recurrence after initial treatment.

$9.7B

2030 Market Size

Projected recurrent ovarian cancer treatment market by 2030.

Potential pathways to Orphan Drug and Breakthrough Therapy designations support accelerated regulatory review.

See the Preclinical Data.

Review the validation results that establish CARG-2020 as a recurrence-prevention candidate.
View Validation

Or see all programs in the pipeline